STOCK TITAN

Pds Biotechnology Corporation Stock Price, News & Analysis

PDSB Nasdaq

Welcome to our dedicated page for Pds Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on Pds Biotechnology Corporation stock.

PDS Biotechnology Corporation (NASDAQ: PDSB) delivers innovative immunotherapies through its Versamune® platform, targeting cancers and infectious diseases. This news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and corporate developments.

Access primary-source press releases and curated analysis covering PDSB's clinical trials, partnership announcements, and financial disclosures. Track progress across key areas: Phase II/III oncology studies, FDA communications, and strategic collaborations enhancing their nanoparticle-based therapies.

Our repository ensures you stay informed about critical developments in HPV-associated cancer treatments, combination therapy research, and infectious disease vaccine progress. Bookmark this page for direct access to PDSB's verified updates, eliminating the need to scour multiple sources.

Rhea-AI Summary

PDS Biotech (Nasdaq: PDSB) announced breakthrough results from its VERSATILE-002 Phase 2 clinical trial, showing exceptional survival outcomes for head and neck cancer patients with low PD-L1 expression. The combination of PDS0101 with Keytruda® achieved a remarkable median overall survival (mOS) of 29.5 months in patients with CPS 1-19, significantly outperforming current standards of care.

The results are particularly significant as they demonstrate nearly triple the survival time compared to Keytruda® alone (10.8 months) or Keytruda® plus chemotherapy (12.3 months) in this difficult-to-treat patient population. Approximately 60% of enrolled patients (n=53) had low PD-L1 expression, with 32 patients in the CPS 1-19 cohort showing these remarkable results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

PDS Biotechnology (NASDAQ: PDSB), a late-stage immunotherapy company focused on cancer treatment, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The event will be held both in-person in New York and virtually from September 8-10, 2025.

CEO Frank Bedu-Addo and CFO Lars Boesgaard will be available for one-on-one meetings with investors during the conference. Interested investors should coordinate through their H.C. Wainwright representatives to schedule meetings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
conferences
-
Rhea-AI Summary

PDS Biotechnology (Nasdaq: PDSB) has announced final topline survival data from its VERSATILE-002 Phase 2 clinical trial evaluating PDS0101 + Keytruda® in HPV16-positive first-line recurrent/metastatic head and neck cancer patients. The study demonstrated a remarkable median overall survival (mOS) of 39.3 months in patients with CPS ≥ 1, significantly outperforming the best published standard of care result of 17.9 months.

The trial enrolled 53 patients and showed durable patient survival promoted by high levels of long-lasting HPV16-specific CD8+ T cells. The treatment combination was well-tolerated with no patients discontinuing due to treatment-related adverse events. The company plans to publish the full dataset later this year, while its VERSATILE-003 Phase 3 trial is currently in progress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.24%
Tags
Rhea-AI Summary

PDS Biotech (NASDAQ: PDSB) reported its Q2 2025 financial results and provided clinical updates. The company reported a net loss of $9.4 million ($0.21 per share), compared to $8.3 million in Q2 2024. Key highlights include positive progress in the VERSATILE-003 Phase 3 trial evaluating PDS0101 for HPV16-positive head and neck cancer.

The company's colorectal cancer cohort in their Phase 2 trial met expansion criteria with promising response rates of ≥6 of 9 confirmed objective responses. Research and development expenses decreased to $4.2 million from $4.5 million year-over-year. The company's cash position stood at $31.9 million as of June 30, 2025, down from $41.7 million at the end of 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.69%
Tags
-
Rhea-AI Summary

PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company specializing in cancer treatment, has scheduled its second quarter 2025 financial results conference call and webcast for August 13, 2025, at 8:00 AM ET.

During the call, management will discuss Q2 2025 financial performance and provide updates on the company's clinical programs. Investors can join via phone using domestic (1-877-704-4453) or international (1-201-389-0920) dial-in numbers, or through the webcast available on PDS Biotech's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences earnings
-
Rhea-AI Summary

PDS Biotechnology (NASDAQ:PDSB) announced successful completion of Stage 1 in their Phase 2 clinical trial for PDS01ADC in metastatic colorectal cancer patients. The trial, conducted in collaboration with the National Cancer Institute (NCI), met the pre-set RECIST v1.1 criteria for expansion into Stage 2, achieving at least 6 objective responses among 9 participants.

The study combines PDS01ADC with floxuridine (FUDR) administered via hepatic artery infusion pump. The trial includes three cohorts: metastatic colorectal cancer, cholangiocarcinoma, and adrenocortical cancer. Following this milestone, the colorectal cancer cohort will expand enrollment to 22 participants, with completion expected by Q4 2025.

PDS01ADC is a novel antibody drug conjugate targeting exposed DNA in tumor necrosis regions, designed to deliver IL-12 with minimal systemic exposure and reduced toxicity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
Rhea-AI Summary
PDS Biotechnology (PDSB) announced a virtual Key Opinion Leader event scheduled for June 17, 2025, focusing on HPV16-positive head and neck squamous cell carcinoma (HNSCC). The event will feature experts Dr. Kevin Harrington and Dr. Katharine Price discussing the unmet needs and treatment landscape for recurrent/metastatic HPV16+ HNSCC. The webinar will examine HNSCC in relation to Merck's KEYNOTE-689 study and address the increasing cases of HPV16+ HNSCC in the US and Europe. A key focus will be Versamune® HPV, PDS Biotech's investigational immunotherapy currently in Phase 3 trials in combination with pembrolizumab for first-line treatment of R/M HPV16+ HNSCC, as well as in Phase 2 trials for various HPV16-positive cancers. The event will explore the differences between HPV-positive and HPV-negative HNSCC as distinct diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
-
Rhea-AI Summary
PDS Biotech (PDSB) presented updated data from the VERSATILE-002 trial evaluating Versamune HPV (PDS0101) for head and neck cancers at ASCO 2025. The trial showed durable median overall survival of 30.0 months in first-line recurrent/metastatic HPV16-positive HNSCC patients, with a 95% CI lower limit of 23.9 months. The study demonstrated an objective response rate of 35.8% and disease control rate of 77.4% across all patients (CPS ≥ 1). Notably, patients with CPS ≥ 20 showed improved outcomes with 39.3 months median overall survival and 47.6% objective response rate. The results are particularly significant as HPV16-positive HNSCC represents over 50% of HNSCC cases in the US and has shown worse survival outcomes compared to other HNSCC types. VERSATILE-003, the company's ongoing Phase 3 trial, is the only registrational study specifically targeting HPV16-positive HNSCC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
-
Rhea-AI Summary
PDS Biotech (NASDAQ: PDSB) announced significant extended follow-up data from its VERSATILE-002 trial and additional studies of Versamune® HPV to be presented at ASCO 2025. The VERSATILE-002 trial showed remarkable survival rates in HPV16-positive head and neck cancer patients: 39.3 months median overall survival for CPS ≥20 patients (vs ~15 months with pembrolizumab alone) and 30.0 months for CPS ≥1 patients (vs ~12 months with pembrolizumab). The ongoing Phase 3 VERSATILE-003 trial will enroll 351 patients to evaluate Versamune® HPV with pembrolizumab as first-line treatment. Additionally, a Phase 2 trial showed promising results with 70% stable disease rate using Versamune® HPV alone and 100% stable disease or partial response when combined with pembrolizumab in newly diagnosed patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
Rhea-AI Summary

PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company specializing in cancer treatment, announced its participation in the A.G.P. Virtual Annual Healthcare Company Showcase on May 21, 2025. CEO Frank Bedu-Addo will engage in a fireside chat from 5:20 to 5:40 p.m. ET. The virtual event will provide opportunities for one-on-one investor meetings with the PDS Biotech leadership team. A replay and transcript of the fireside chat will be available on the company's website after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.64%
Tags
conferences

FAQ

What is the current stock price of Pds Biotechnology Corporation (PDSB)?

The current stock price of Pds Biotechnology Corporation (PDSB) is $0.9473 as of October 10, 2025.

What is the market cap of Pds Biotechnology Corporation (PDSB)?

The market cap of Pds Biotechnology Corporation (PDSB) is approximately 46.4M.
Pds Biotechnology Corporation

Nasdaq:PDSB

PDSB Rankings

PDSB Stock Data

46.36M
45.22M
3.03%
15.89%
3.93%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON